Nextwave patents expiration
1. Quillivant Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | NEXTWAVE | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | |
| US8778390 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8956649 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8465765 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US9040083 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8287903 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8563033 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 27, 2015 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treatin...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
How can I launch a generic of QUILLIVANT XR before it's drug patent expiration?
More Information on Dosage
QUILLIVANT XR family patents
